TY - JOUR
T1 - Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies
AU - Futagami, Masayuki
AU - Yokoyama, Yoshihito
AU - Shimada, Muneaki
AU - Sato, Shinya
AU - Miyagi, Etsuko
AU - Tozawa-Ono, Akiko
AU - Suzuki, Nao
AU - Fujimura, Masaki
AU - Aoki, Yoichi
AU - Sagae, Satoru
AU - Sugiyama, Toru
N1 - Funding Information:
Nao Suzuki has received research support through grants from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Shionogi & Co., Ltd., Tsumura & Co., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., CSL Behring K.K., ICREO Co., Ltd., Merck Serono Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Atom Medical Corporation; and has received compensation from Novartis Pharma K.K., Kyowa Hakko Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., CSL Behring K.K., Merck Serono Co., Ltd., Takeda Pharmaceutical Co, Ltd., Daiichi Sankyo Co, Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Pfizer Japan Inc., and Ferring Pharmaceuticals Co., Ltd. for service as a consultant.
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.
AB - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.
KW - Gynecological malignancies
KW - JGOG
KW - QOL
KW - Supportive and Palliative Care Committee
UR - http://www.scopus.com/inward/record.url?scp=85015745976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015745976&partnerID=8YFLogxK
U2 - 10.1007/s11912-017-0580-y
DO - 10.1007/s11912-017-0580-y
M3 - Review article
C2 - 28303492
AN - SCOPUS:85015745976
VL - 19
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 4
M1 - 25
ER -